Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Change in lesion location from extrafoveal to subfoveal in participants who developed GA in fellow eye is reported. Lesion location was assessed at index diagnosis and at each year, then stratified by whether a patient developed GA in the 5 years post diagnosis. Changes in lesion were calculated as the difference in the number of participants with extrafoveal location at index diagnosis of the study eye, compared to the number of participants with extrafoveal lesion in the study eye at each year.

Time frame: From index date of GA diagnosis up to 5 years

Population: Participants with GA at the index date and five years of follow-up data who developed GA in the fellow eye after the index date. The populations were different for each year since only patients with lesion location information contributed to each cohort. Only participants with appropriate follow up were analyzed.

Change in lesion location from extrafoveal to subfoveal in participants who developed wAMD in study eye is reported. Lesion location was assessed at index diagnosis and at each year, then stratified by whether a patient developed wAMD in the 5 years post diagnosis. Changes in lesion were calculated as the difference in the number of participants with extrafoveal location at index diagnosis of the study eye, compared to the number of participants with extrafoveal lesion in the study eye at each year.

Time frame: From index date of GA diagnosis up to 5 years

Population: Participants with GA at index date and five years of follow-up data who developed wAMD in the study eye after the index date. The populations were different for each year since only patients with lesion location information contributed to each cohort. Only participants with appropriate follow up were analyzed.

Change in visual acuity (VA) in participant's study eye is reported. Study eye is defined as the first eye with the disease, and fellow eye, the participant's second eye. Change in VA was determined by calculating the difference between mean visual acuity (VA) readings at index diagnosis, and mean at another timepoint, assessed yearly for participants with valid VA readings at both timepoints.

Time frame: From index date of GA diagnosis up to 5 years

Population: Participants with GA at the index date and at least one year of follow-up data, with a VA reading at index, and at least one more VA reading at a subsequent follow-up year. The populations were different for each year since patients should have certain follow-up information to contribute to each cohort, and some participants had data in more than one year. Only those participants with VA readings at appropriate timepoints, with appropriate follow up, were analyzed.

Number of participants who developed or progressed to age-related macular degeneration (wAMD) in the study eye is reported. The criteria used to determine progression through development to wAMD was identifying when ICD (International Classification of Diseases) codes for wAMD were present in the study eye.

Time frame: From index date of GA diagnosis up to 5 years.

Population: Participants with GA at the index date and at least one year of follow-up data, excluding patients with wAMD prior to index. Only participants with appropriate follow up were analyzed. The populations were different for each year since patients should have certain follow-up information to contribute to each cohort, and some participants had data in more than one year.

Number of participants who developed or progressed to geographic atrophy (GA) in the fellow eye is reported. For patients diagnosed with GA at baseline, the development of GA in the fellow eye was closely monitored over time, with progress tracked for each year.

Time frame: From index date of GA diagnosis up to 5 years.

Population: Participants with GA at the index date and at least one year of follow-up data, excluding bilateral patients at index. Only participants with appropriate follow up were analyzed. The populations were different for each year since patients should have certain follow-up information to contribute to each cohort, and some participants had data in more than one year.

Incidence and prevalence of GA over time is reported. This endpoint analyzed the yearly counts of newly diagnosed or prevalent cases to help in understanding the progression of the overall disease.

Time frame: Number of yearly counts of GA from 2018 to 2013, by quarterly average.

Population: Participants newly diagnosed with GA by quarterly average per year, for 2018-2023. Given the nature of the database, it was not possible to assess the prevalence or incidence of GA, but the absolute numbers of first time GA diagnosis, which is presented here.

The number of participants with corneal transplant during the observational period is reported.

Time frame: Total number of participants with corneal transplants were documented from index date up to 5 years.

Population: Participants with GA were tracked longitudinally (yearly) from index date of GA diagnosis in the database for occurrence of corneal transplantation.

Number of participants with incisional glaucoma surgery during the observational period is reported.

Time frame: Total number of participants with incisional glaucoma surgery were documented from index date up to 5 years.

Population: Participants with GA were tracked longitudinally (yearly) from index date of GA diagnosis in the database for occurrence of incisional glaucoma surgery.

Number of participants with vitrectomy during the observational period is reported.

Time frame: Total number of participants with vitrectomy were documented from index date up to 5 years.

Population: Participants with GA were tracked longitudinally (yearly) from index date of GA diagnosis in the database for occurrence of vitrectomy.

The retinal disease-related healthcare resource utilization (HCRU) outcome, number of anti-vascular endothelial growth factor (anti-VEGF) injections per quarter in a year is reported.

Time frame: Mean number of quarterly anti-VEGF injections from 2019 up to 2023.

Population: Participants were evaluated from index diagnosis and last encounter date, including patients in quarters with no anti-VEGF treatments, without filtering on follow-up information. Results are presented only for first quarters of 2019 to 2023 respectively.

The retinal disease-related HCRU outcome, number of ocular comorbidities by year of follow up is reported.

Time frame: Total number of participants with ocular comorbidities were documented from index date up to 5 years.

Population: Participants with GA were tracked longitudinally (yearly) from index date of GA diagnosis in the database for occurrence of ocular comorbidities.

The retinal disease-related healthcare resource utilization (HCRU) outcome, number of visits by participants per quarter in a year is reported.

Time frame: Mean number of quarterly visits from 2019 up to 2023.

Population: Participants were evaluated from the incident date of GA and assessed on a yearly basis for changes in physician habits over time. A patient visit or encounter was identified in the database any time a patient visited one of the panel physicians, without filtering on follow-up information. Results are presented only for first quarters of 2019 to 2023 respectively.